Deliver Therapeutics applies high-throughput DNA encoded library (DEL) screening to discover novel small molecule therapeutics for challenging clinical indications. The company focuses on developing best-in-class inhibitors targeting key tyrosine kinases to overcome cancer resistance mechanisms. Additionally, they are developing senomorphic therapies using selective JAK inhibitors to regulate the senescence-associated secretory phenotype (SASP) in age-related diseases.

FIZE Medical's FIZE kUO platform utilizes AI-driven continuous monitoring to provide real-time urine output data, enhancing the precision of kidney function assessment in critically ill patients. This technology addresses the challenge of delayed diagnosis in acute kidney injury (AKI) by enabling timely interventions based on accurate, actionable metrics.

HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.

Labs develops human-enhancement technologies that utilize artificial intelligence, immersive realities, and consumer-wearables to foster community engagement and improve individual capabilities. The company addresses the need for interconnected social experiences and sustainable practices by providing tools that empower users to learn, create, and collaborate effectively.

Provides a shared progress tracking platform for coaches and clients, enabling clients to log actions, track goals, and maintain accountability between sessions. Coaches gain measurable insights into client progress and engagement through customizable logs, reminders, and real-time feedback tools, improving the effectiveness of their practice.

MEDiC utilizes a proprietary CRISPR functional genomics platform combined with 3D tumor models to identify cancer biomarkers and novel drug targets with high precision. This approach addresses the challenge of missed potential biomarkers in current drug development, enhancing the accuracy of patient stratification for oncology treatments.

NEX provides a suite of controllable AI image generation tools that utilize IP-consistent models trained on securely stored team data, enabling precise customization of images through multimodal inputs. This technology addresses the inefficiencies in creative workflows by allowing teams to rapidly generate high-quality images tailored to specific project requirements, significantly reducing model development costs and turnaround times.

This company develops a topical treatment using targeted nanoparticles to eliminate p16-expressing keratinocytes, addressing aging-related skin conditions. Their technology aims to treat conditions like actinic keratosis and UV-damaged skin by selectively removing problematic cells.

Poseida Therapeutics utilizes its proprietary non-viral piggyBac® DNA Delivery System and Cas-CLOVER™ Site-Specific Gene Editing System to develop allogeneic CAR-T therapies targeting life-threatening cancers and genetic diseases. The company aims to provide functional cures and improved treatment options for patients suffering from multiple myeloma and rare genetic disorders.

Rise is an AI-powered job search platform that utilizes machine learning algorithms to deliver personalized job recommendations based on user profiles and preferences. The platform enhances the job search experience for over 5 million users by providing tailored insights and timely alerts for relevant job openings.

SCL is a school management system that integrates educational and administrative modules to automate attendance tracking, grade management, and communication among teachers, students, and parents. This system enhances operational efficiency for educational institutions by reducing manual administrative tasks and improving information flow.

GEROTHERAPEUTIX develops gerotherapeutics targeting the underlying biological processes of aging to extend healthspan and reduce disease burden. The company utilizes proprietary MitoXcel geropeptides that focus on mitochondrial function to achieve systemic health improvements. This approach aims to deliver broad phenotypic healthspan benefits without targeting individual age-related diseases.